Groundbreaking immunomodulation – towards safer and more targeted treatments for autoimmune diseases

Purpose and goal

The project aims to validate a new treatment principle for autoimmune diseases by developing and testing small molecule inhibitors of the protein Endophilin A2 (EA2). The overall goal is to identify a drug candidate with potential to offer safer and more targeted treatment for diseases such as SLE and RA.

Expected effects and result

The project is expected to result in a drug candidate with documented efficacy in human immune cells for continued preclinical development. The results will reduce development risk, attract investments and ultimately enable new treatments that improve the quality of life for patients, especially women, who are disproportionately affected by autoimmune disease.

Planned approach and implementation

The project consists of two phases: (1) biochemical validation of EA2 inhibitors and (2) functional testing in human immune cells. The work is being carried out in collaboration with leading expert organizations and is led by Serendo Therapeutics with support from researchers and advisors in immunology and drug development.